|
1
|
Bellissimo F, Pinzone MR, Cacopardo B and
Nunnari G: Diagnostic and therapeutic management of hepatocellular
carcinoma. World J Gastroenterol. 21:12003–12021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thomas MB, Jaffe D, Choti MM, Belghiti J,
Curley S, Fong Y, Gores G, Kerlan R, Merle P, ONeil B, et al:
Hepatocellular carcinoma: Consensus recommendations of the National
Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol.
28:3994–4005. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crissien AM and Frenette C: Current
management of hepatocellular carcinoma. Gastroenterol Hepatol (NY).
10:3994–4005. 2014.
|
|
4
|
Balogh J, Victor D III, Asham EH,
Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM and Monsour
HP Jr: Hepatocellular carcinoma: A review. J Hepatocell Carcinoma.
3:41–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao ZC, Zheng SS, Wan YL, Jia CK and Xie
HY: The molecular mechanism underlying angiogenesis in
hepatocellular carcinoma: The imbalance activation of signaling
pathways. Hepatobiliary Pancreat Dis Int. 2:529–536.
2003.PubMed/NCBI
|
|
8
|
Kawaji H, Severin J, Lizio M, Forrest AR,
van Nimwegen E, Rehli M, Schroder K, Irvine K, Suzuki H, Carninci
P, et al: Update of the FANTOM web resource: From mammalian
transcriptional landscape to its dynamic regulation. Nucleic Acids
Res. 39:(Database). D856–D860. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amorim M, Salta S, Henrique R and Jerónimo
C: Decoding the usefulness of non-coding RNAs as breast cancer
markers. J Transl Med. 14:2652016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beermann J, Piccoli MT, Viereck J and Thum
T: Non-coding RNAs in development and disease: Background,
mechanisms, and therapeutic approaches. Physiol Rev. 96:1297–1325.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arora A, Singh S, Bhatt AN, Pandey S,
Sandhir R and Dwarakanath BS: Interplay between metabolism and
oncogenic process: Role of microRNAs. Transl Oncogenomics. 7:11–27.
2015.PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu X, Li Z, Yu J, Chan MT and Wu WK:
MicroRNAs predict and modulate responses to chemotherapy in
colorectal cancer. Cell Prolif. 48:503–510. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wen Y, Han J, Chen J, Dong J, Xia Y, Liu
J, Jiang Y, Dai J, Lu J, Jin G, et al: Plasma miRNAs as early
biomarkers for detecting hepatocellular carcinoma. Int J Cancer.
137:1679–1690. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu S, Tao R, Wang S, Wang C, Zhao X, Zhao
H, Li L, Zhu S, He Y, Jiang X, et al: MicroRNA-21 promotes cell
proliferation in human hepatocellular carcinoma partly by targeting
HEPN1. Tumour Biol. 36:5467–5472. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH,
Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al: The putative
tumour suppressor microRNA-124 modulates hepatocellular carcinoma
cell aggressiveness by repressing ROCK2 and EZH2. Gut. 61:278–289.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang JP, Zeng C, Xu L, Gong J, Fang JH
and Zhuang SM: MicroRNA-148a suppresses the epithelial-mesenchymal
transition and metastasis of hepatoma cells by targeting Met/Snail
signaling. Oncogene. 33:4069–4076. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lai YY, Shen F, Cai WS, Chen JW, Feng JH,
Cao J, Xiao HQ, Zhu GH and Xu B: MiR-384 regulated IRS1 expression
and suppressed cell proliferation of human hepatocellular
carcinoma. Tumour Biol. 37:14165–14171. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xue D, Zhou C, Lu H, Xu R, Xu X and He X:
LncRNA GAS5 inhibits proliferation and progression of prostate
cancer by targeting miR-103 through AKT/mTOR signaling pathway.
Tumour Biol. Oct 14–2016.(Epub Epub ahead of print). View Article : Google Scholar
|
|
22
|
Yim GW, Kim HJ, Kim LK, Kim SW, Kim S, Nam
EJ and Kim YT: Long non-coding RNA HOXA11 antisense promotes cell
proliferation and invasion and predicts patient prognosis in serous
ovarian cancer. Cancer Res Treat. Oct 11–2016.(Epub Epub ahead of
print). View Article : Google Scholar :
|
|
23
|
Wang J, Ye C, Xiong H, Shen Y, Lu Y, Zhou
J and Wang L: Dysregulation of long non-coding RNA in breast
cancer: an overview of mechanism and clinical implication.
Oncotarget. 8:5508–5522. 2016.
|
|
24
|
Liu YR, Tang RX, Huang WT, Ren FH, He RQ,
Yang LH, Luo DZ, Dang YW and Chen G: Long noncoding RNAs in
hepatocellular carcinoma: Novel insights into their mechanism.
World J Hepatol. 7:2781–2791. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi
Y and Guo J: Long noncoding RNA associated-competing endogenous
RNAs in gastric cancer. Sci Rep. 4:60882014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu L, Ye H, Huang G, Luo F, Liu Y, Liu Y,
Yang X, Shen J, Liu Q and Zhang J: Long noncoding RNA GAS5
suppresses the migration and invasion of hepatocellular carcinoma
cells via miR-21. Tumour Biol. 37:2691–2702. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deng J, He M, Chen L, Chen C, Zheng J and
Cai Z: The loss of miR-26a-mediated post-transcriptional regulation
of cyclin E2 in pancreatic cancer cell proliferation and decreased
patient survival. PLoS One. 8:e764502013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao J, Li L, Wu M, Liu M and Xie X, Guo J,
Tang H and Xie X: MiR-26a inhibits proliferation and migration of
breast cancer through repression of MCL-1. PLoS One. 8:e651382013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y,
Xu X, Wu J, Li S, Mao Q, et al: miR-26a inhibits proliferation and
motility in bladder cancer by targeting HMGA1. FEBS Lett.
587:2467–2473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Deng M, Tang HL, Lu XH, Liu MY, Lu XM, Gu
YX, Liu JF and He ZM: miR-26a suppresses tumor growth and
metastasis by targeting FGF9 in gastric cancer. PLoS One.
8:e726622013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Braconi C, Kogure T, Valeri N, Huang N,
Nuovo G, Costinean S, Negrini M, Miotto E, Croce CM and Patel T:
microRNA-29 can regulate expression of the long non-coding RNA gene
MEG3 in hepatocellular cancer. Oncogene. 30:4750–4756. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo P, Lan J, Ge J, Nie Q, Guo L, Qiu Y
and Mao Q: MiR-26a enhances the radiosensitivity of glioblastoma
multiforme cells through targeting of ataxia-telangiectasia
mutated. Exp Cell Res. 320:200–208. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen W, Song M, Liu J, Qiu G, Li T, Hu Y
and Liu H: MiR-26a promotes ovarian cancer proliferation and
tumorigenesis. PLoS One. 9:e868712014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu B, Wu X, Liu B, Wang C, Liu Y, Zhou Q
and Xu K: MiR-26a enhances metastasis potential of lung cancer
cells via AKT pathway by targeting PTEN. Biochim Biophys Acta.
1822:1692–1704. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao S, Ye X, Xiao L, Lian X, Feng Y, Li F
and Li L: MiR-26a inhibits prostate cancer progression by
repression of Wnt5a. Tumour Biol. 35:9725–9733. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guo K, Zheng S, Xu Y, Xu A, Chen B and Wen
Y: Loss of miR-26a-5p promotes proliferation, migration, and
invasion in prostate cancer through negatively regulating SERBP1.
Tumour Biol. 37:12843–12854. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Melo SA and Esteller M: Dysregulation of
microRNAs in cancer: Playing with fire. FEBS Lett. 585:2087–2099.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sandhu R, Rivenbark AG and Coleman WB:
Loss of post-transcriptional regulation of DNMT3b by microRNAs: A
possible molecular mechanism for the hypermethylation defect
observed in a subset of breast cancer cell lines. Int J Oncol.
41:721–732. 2012.PubMed/NCBI
|
|
39
|
Nishida N, Nishimura T, Nakai T, Chishina
H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, et
al: Genome-wide profiling of DNA methylation and tumor progression
in human hepatocellular carcinoma. Dig Dis. 32:658–663. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen WC, Chen MF and Lin PY: Significance
of DNMT3b in oral cancer. PLoS One. 9:e899562014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu Z, Wang L, Wang LE, Sturgis EM and Wei
Q: Polymorphisms of the DNMT3B gene and risk of squamous cell
carcinoma of the head and neck: A case-control study. Cancer Lett.
268:158–165. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fan H, Chen L, Zhang F, Quan Y, Su X, Qiu
X, Zhao Z, Kong KL, Dong S, Song Y, et al: MTSS1, a novel target of
DNA methyltransferase 3B, functions as a tumor suppressor in
hepatocellular carcinoma. Oncogene. 31:2298–2308. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhao J, Dahle D, Zhou Y, Zhang X and
Klibanski A: Hypermethylation of the promoter region is associated
with the loss of MEG3 gene expression in human pituitary tumors. J
Clin Endocrinol Metab. 90:2179–2186. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang X, Gejman R, Mahta A, Zhong Y, Rice
KA, Zhou Y, Cheunsuchon P, Louis DN and Klibanski A: Maternally
expressed gene 3, an imprinted noncoding RNA gene, is associated
with meningioma pathogenesis and progression. Cancer Res.
70:2350–2358. 2010. View Article : Google Scholar : PubMed/NCBI
|
